AbbVie Bets Enchant v3 Multimodal AI Across Three Therapeutic Areas

What changed

AbbVie and Iambic announced on 21 September 2026 a multi year collaboration to accelerate small molecule discovery across immunology, neuroscience, and oncology. Iambic will apply its Enchant v3 multimodal transformer, trained on more than 6,000 molecular properties, alongside structure prediction tools including NeuralPLexer for protein ligand complexes.

Iambic receives an upfront payment plus success based milestones and tiered royalties on collaboration products. AbbVie framed the deal as equipping discovery scientists with fit for purpose AI rather than generic chat tools. No pre existing programs transfer under the agreement.

Why it matters

Large pharma is standardizing on named multimodal models with disclosed training corpora instead of one off vendor pilots. AbbVie's scale signals that parallel multi parameter optimization, not sequential property filtering, is becoming the procurement default for small molecule desks.

Who is affected

Medicinal chemistry leaders at mid cap biotechs, AI platform vendors competing with Iambic's Enchant stack, and investors tracking whether 2026 partnership density converts to IND filings within 24 months.

What to do next

If you run discovery partnerships, require explicit modality coverage, structure prediction integration, and milestone tables before replacing legacy cheminformatics stacks.

What to watch

First disclosed candidate series advanced under the AbbVie collaboration, and whether Iambic publishes Enchant v3 benchmark deltas against prior generation models on rare property classes.

Sources

1. Primary. AbbVie via PR Newswire, AbbVie and Iambic Announce Collaboration to Accelerate AI driven Drug Discovery (21 September 2026). Deal scope, Enchant v3 description, and payment structure.
2. Secondary. Iambic, AbbVie and Iambic collaboration announcement (21 September 2026). Company confirmation and executive quotes.